Biotechnology
LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation
Key Highlights: * Cynata to collaborate with Leiden University Medical Center (LUMC) in the Netherlands, in a new clinical trial in patients who have received a kidney transplant * Trial to be funded by LUMC; Cynata will supply iPSC-derived Cymerus mesenchymal stem cells (MSCs) at its cost t...
2022-11-04 09:15
2622
Aquavit Celebrates Judgment Imposing Permanent Ban On Counterfeiters
NEW YORK, Nov. 4, 2022 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. ("Aquavit") secured a long-awaited and much-deserved judgment against counterfeiters. After nearly four years of court proceedings, the Honorable Valerie E. Caproni ofthe United States District Court for the Southern District o...
2022-11-04 01:37
2685
Kira Pharmaceuticals Presents Complete Data from Phase 1 SYNERGY-1 Trial of KP104 at American Society for Nephrology Kidney Week 2022
Biomarker data demonstrates proof-of-concept for KP104's dual-targeting mechanism via dose-dependent inhibition of alternative and terminal pathways and supports intravenous and subcutaneous administration of KP104 in phase 2 studies CAMBRIDGE, Mass. and SUZHOU, JIANGSU, China, Nov. 3, 2022 /PRN...
2022-11-03 21:30
2272
Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition
BCMA/CD19 dual-targeting FasTCAR-T GC012F demonstrated 100% ORR and 100% MRD negativity in the 13 patients treated SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Nov. 3, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharm...
2022-11-03 21:10
1827
Yuyu Pharma attendance at European Pharmaceutical Conference
SEOUL, South Korea, Nov. 3, 2022 /PRNewswire/ -- Robert Yu, CEO of Yuyu Pharma,
has been attending biopharmaceutical conferences held inGermany, BIO-Europe and
CPHI. The purpose is to explore opportunities to expand into international
markets, such as Europe.
2022-11-03 21:00
1680
Five New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation
The FDA gave positive feedback regarding filing a Biologics License Application (BLA) for Sjögren's syndrome following two Phase 3 studies Ainos is seeking out-licensing opportunities to accelerate the process of bringing five new drug candidates to Phase 3 trials and eventual commercialization ...
2022-11-03 19:00
1447
DOUBLE HONORS FOR AMGEN WITH GREAT PLACE TO WORK™ CERTIFICATIONS FOR BOTH ITS SINGAPORE ENTITIES IN 2022
SINGAPORE, Nov. 3, 2022 /PRNewswire/ -- Amgen announced both its entities in Singapore - Amgen Singapore Manufacturing (ASM) and its commercial affiliate Amgen Biotechnology Singapore (ABS), have been awarded Great Place to Work® certifications in the 'medium and large' workplace category for 202...
2022-11-03 16:43
3188
NeuroXess Shares Latest Breakthoughs in Life Sciences at Sequoia Talk
SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- Peng Lei, CEO of NeuroXess, a Sequoia firm, was invited to participate in Sequoia China's Sequoia Talk Series on "The Compound Interest of Innovation" at which he shared his knowledge of and experience with the latest technological innovations in the field o...
2022-11-03 15:03
1873
Turn Biotechnologies Names 25-year Biotech Industry Veteran Richard Peterson Chief Financial Officer
Seasoned Executive has Successful Track Record Working with Global Investors to Raise Billions of Dollars MOUNTAIN VIEW, Calif., Nov. 2, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today annou...
2022-11-02 21:00
2570
Antengene Announces IND Approval for the Phase I STAMINA-001 Study to Evaluate ATG-037 (CD73 Inhibitor) for the Treatment of Locally Advanced or Metastatic Solid Tumors in China
- ATG-037, an inhouse asset developed by Antengene and with global rights, has been approved to enter clinical studies inAustralia and China, thus becoming the firstoral small molecule CD73 inhibitor entering the clinical-stage in China and the wider Asia Pacific region. ATG-037 IND in Austr...
2022-11-02 20:07
2382
Dr Amit Kakar joins MedGenome Board of Directors
* The company has also added Navjeewan Khosla from Novo Holdings as Board Observer. * The company had announced a $50 million Series D investment led by Novo Holdings inAugust 2022. BANGALORE, India, Nov. 2, 2022 /PRNewswire/ -- MedGenome is a leading provider of genomic solutions for populat...
2022-11-02 10:00
1922
Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19
-- ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3-chymotrypsin like protease (3CLpro) -- In antiviral cellular assays with infectious SARS-CoV-2, ASC11 demonstrated higher potency against SARS-CoV-2 than other 3CLpro inhibitors including Nirmatrelvir, S-217622, P...
2022-11-02 08:10
2041
SK pharmteco appoints Joerg Ahlgrimm as CEO to spearhead the next phase of company growth and innovation
- Joerg Ahlgrimm brings 25 years of expertise in pharmaceuticals and innovative cell and gene therapies - SK pharmteco expands pharmaceutical drug production and advances cell and gene therapy production - Annual sales expected to exceed KRW 1 trillion in 2022 FRANKFURT, Germany, Nov. 2, 2022 /PR...
2022-11-02 02:00
1785
I Peace partners with the California Institute for Regenerative Medicine [CIRM]
PALO ALTO, Calif., Nov. 1, 2022 /PRNewswire/ -- I Peace, Inc. (
https://www.ipeace.com
2022-11-02 00:00
1999
Real-World Application of Lunit INSIGHT to be Spotlighted at RSNA 2022 (Oral Presentations)
* 7 oral presentations and 1 e-poster highlighting Lunit's most up-to-date research on its AI solution for radiology, have been accepted by RSNA * Program will include studies evaluating the performance of Lunit's commercial AI software across massive real-world population groups * Software ...
2022-11-01 22:00
2142
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives NMPA Approval for the Treatment of sqNSCLC
SHANGHAI, Nov. 1, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that its first self-developed innovative anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (generic name: serplulimab injection), in combination with carboplatin and albumin-bound paclitaxel for the first-lin...
2022-11-01 21:32
2996
Immuno Cure appoints new CFO
Strengthening of executive management team to propel growth strategy HONG KONG, Nov. 1, 2022 /PRNewswire/ -- Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in DNA vaccines and immunotherapies, announced today the appointment of Mr M...
2022-11-01 20:18
2536
Hummingbird Bioscience to Attend the Credit Suisse 31st Annual Healthcare Conference
SAN FRANCISCO, HOUSTON and SINGAPORE, Nov. 1, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Chief Financial OfficerJosh House and Chief Deve...
2022-11-01 20:00
1309
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis
NEWTON, Mass. and FLORENCE, Italy, Nov. 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today anno...
2022-11-01 19:40
1942
Citeline and Norstella Complete Merger to Form a $5 Billion Global Pharmaceutical Technology Company
With more than 1,600 employees across the globe, the new organization is now one of the world's largest pharma intelligence solutions providers on the market YARDLEY, Pa., Nov. 1, 2022 /PRNewswire/ -- Norstella, a global leader with end-to-end solutions that smooth access to life-saving therapies...
2022-11-01 19:00
3011
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 273 media titles]
2024-04-24 17:09
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
6378
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
2024-04-22 16:00
4460
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
2024-04-22 06:00
4054
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
2024-04-24 17:09
3188
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
2024-04-23 15:43
3117